Document headings vary by document type but may contain
                    the following: the agency or agencies that issued and signed a document
the number of the CFR title and the number of each part
                      the document amends, proposes to amend, or is directly
                      related to
the agency docket number / agency internal file number
the RIN which identifies each regulatory action listed in
                      the Unified Agenda of Federal Regulatory and Deregulatory
                      Actions See the
                    Document Drafting Handbook
                    for more details.
 Department of Health and Human Services Office of the Secretary 21 CFR Ch. I
25 CFR Ch. V
42 CFR Chs. I-V
45 CFR Subtitle A; Subtitle B, Chs. II, III, and XIII
 AGENCY: Office of the Secretary, HHS.
 ACTION: Semiannual Regulatory Agenda.
 SUMMARY: The Regulatory Flexibility Act of 1980 and Executive Order (EO) 12866 require the semiannual issuance of an inventory of rulemaking actions under development throughout the Department, offering for public review summarized information about forthcoming regulatory actions.
 FOR FURTHER INFORMATION CONTACT: Ann C. Agnew, Executive Secretary, Department of Health and Human Services, 200 Independence Avenue SW., Washington, DC 20201; (202) 690-5627.


SUPPLEMENTARY INFORMATION: The Department of Health and Human Services (HHS) is the Federal government's lead agency for protecting the health of all Americans and providing essential human services, especially for those who are least able to help themselves. HHS enhances the health and well-being of Americans by promoting effective health and human services and by fostering sound, sustained advances in the sciences underlying medicine, public health, and social services. This Agenda presents the regulatory activities that the Department expects to undertake in the foreseeable future to advance this mission. HHS has an agency-wide effort to support the Agenda's purpose of encouraging more effective public participation in the regulatory process. For example, to encourage public participation, we regularly update our regulatory Web page (
                        *http://www.HHS.gov/​regulations*) which includes links to HHS rules currently open for public comment, and also provides a “regulations toolkit” with background information on regulations, the commenting process, how public comments influence the development of a rule, and how the public can provide effective comments. HHS also actively encourages meaningful public participation in its retrospective review of regulations, through a comment form on the HHS retrospective review Web page (
                        *http://www.HHS.gov/​RetrospectiveReview*). The rulemaking abstracts included in this paper issue of the 
                        **Federal Register**
                         cover, as required by the Regulatory Flexibility Act of 1980, those prospective HHS rulemakings likely to have a significant economic impact on a substantial number of small entities. The Department's complete Regulatory Agenda is accessible online at 
                        *http://www.RegInfo.gov.* Ann C. Agnew, Executive Secretary to the Department.
 Office of the Secretary—Completed Actions
Sequence No.
Title
Regulation
                                 Identifier No.92
Removal of 2 CFR Subsection 376.147 
                                **(Rulemaking Resulting From a Section 610 Review)**
0991-AC0893
Uniform Administrative Requirements, Costs Principles and Adult Requirements (45 CFR 75) 
                                **(Rulemaking Resulting From a Section 610 Review)**
0991-AC09
 Substance Abuse and Mental Health Services Administration—Completed Actions
Sequence No.
Title
Regulation
                                 Identifier No.94
Requirements Governing the Use of Seclusion and Restraint in Certain Nonmedical Community-Based Facilities for Children and Youth
0930-AA1095
Medication Assisted Treatment for Opioid Use Disorders Reporting Requirements
0930-AA22
 Centers for Disease Control and Prevention—Completed Actions
Sequence No.
Title
Regulation
                                 Identifier No.96
Establishment of Minimum Standards for Birth Certificates
0920-AA46
 Food and Drug Administration—Final Rule Stage
Sequence No.
Title
Regulation
                                 Identifier No.97
Human Subject Protection; Acceptance of Data From Clinical Investigations for Medical Devices
0910-AG4898
Food Labeling; Gluten-Free Labeling of Fermented, Hydrolyzed, or Distilled Foods
0910-AH0099
Safety and Effectiveness of Consumer Antiseptics; Topical Antimicrobial Drug Products for Over-the-Counter Human Use (Healthcare Antiseptic)
0910-AH40
 
 
 Food and Drug Administration—Long-Term Actions
Sequence No.
Title
Regulation
                                 Identifier No.100
Postmarketing Safety Reporting Requirements for Human Drug and Biological Products
0910-AA97101
Over-the-Counter (OTC) Drug Review—Cough/Cold (Antihistamine) Products
0910-AF31102
Laser Products; Amendment to Performance Standard
0910-AF87103
Updated Standards for Labeling of Pet Food
0910-AG09104
Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products
0910-AG94105
Radiology Devices; Designation of Special Controls for the Computed Tomography X-Ray System
0910-AH03106
General and Plastic Surgery Devices: Sunlamp Products
0910-AH14
 Food and Drug Administration—Completed Actions
Sequence No.
Title
Regulation
                                 Identifier No.107
Medical Gas Containers and Closures; Current Good Manufacturing Practice Requirements
0910-AC53108
Amendment to the Current Good Manufacturing Practice Regulations for Finished Pharmaceuticals—Second Phase
0910-AG20109
Requirements for the Testing and Reporting of Tobacco Product Constituents, Ingredients, and Additives
0910-AG59110
Amendments to the Current Good Manufacturing Practice Regulations for Finished Pharmaceuticals—Components
0910-AG70111
Format and Content of Reports Intended To Demonstrate Substantial Equivalence
0910-AG96112
Investigational New Drug Application Annual Reporting
0910-AH07113
Requirements for Tobacco Product Manufacturing Practice
0910-AH22114
Use of Ozone Depleting Substances (Section 610 Review)
0910-AH36
 Centers for Medicare & Medicaid Services—Proposed Rule Stage
Sequence No.
Title
Regulation
                                 Identifier No.115
CY 2018 Revisions to Payment Policies Under the Physician Fee Schedule and Other Revisions to Medicare Part B (CMS-1676-P) (Section 610 Review)
0938-AT02116
CY 2018 Hospital Outpatient PPS Policy Changes and Payment Rates and Ambulatory Surgical Center Payment System Policy Changes and Payment Rates (CMS-1678-P) (Section 610 Review)
0938-AT03117
CY 2019 Notice of Benefit and Payment Parameters (CMS-9930-P) (Section 610 Review)
0938-AT12
 Centers for Medicare & Medicaid Services—Final Rule Stage
Sequence No.
Title
Regulation
                                 Identifier No.118
Hospital Inpatient Prospective Payment System for Acute Care Hospitals and the Long-Term Care Hospital Prospective Payment System and FY 2018 Rates (CMS-1677-P) (Section 610 Review)
0938-AS98
 Centers for Medicare & Medicaid Services—Long-Term Actions
Sequence No.
Title
Regulation
                                 Identifier No.119
Hospital and Critical Access Hospital (CAH) Changes to Promote Innovation, Flexibility, and Improvement in Patient Care (CMS-3295-F) (Rulemaking Resulting From a Section 610 Review)
0938-AS21
 Centers for Medicare & Medicaid Services—Completed Actions
Sequence No.
Title
Regulation
                                 Identifier No.120
Imaging Accreditation (CMS-3309-P)
0938-AS62121
Merit-Based Incentive Payment System (MIPS) and Alternative Payment Models (APMs) in Medicare Fee-for-Service (CMS-5517-FC) (Completion of a Section 610 Review)
0938-AS69122
CY 2017 Home Health Prospective Payment System Rate Update; Home Health Value-Based Purchasing Model; and Home Health Quality Reporting Requirements (CMS-1648-F) (Completion of a Section 610 Review)
0938-AS80123
CY 2017 Revisions to Payment Policies Under the Physician Fee Schedule and Other Revisions to Medicare Part B (CMS-1654-F) (Completion of a Section 610 Review)
0938-AS81( print page 40280)124
CY 2017 Hospital Outpatient PPS Policy Changes and Payment Rates and Ambulatory Surgical Center Payment System Policy Changes and Payment Rates (CMS-1656-FC) (Completion of a Section 610 Review)
0938-AS82
 DEPARTMENT OF HEALTH AND HUMAN SERVICES (HHS) Office of the Secretary (OS) Completed Actions 92. Removal of 2 CFR Subsection 376.147 (Rulemaking Resulting From a Section 610 Review) *Legal Authority:*5 U.S.C. 301; 31 U.S.C. 6101 *Abstract:*
                         HHS is amending its adoption of the Office of the Management and Budget's Nonprocurement Common Rule, found at 2 CFR part 180. This will remove 2 CFR subsection 376.147, which provides information about the scope of HHS OIG exclusions under title XI of the Social Security Act. *Timetable:* Action
Date
FR CiteWithdrawn
06/08/17
 *Regulatory Flexibility Analysis Required:*
                         Undetermined. *Agency Contact:*
                         Tiffani Redding, Program Analyst, Department of Health and Human Services, Office of the Secretary, 200 Independence Avenue SW., Washington, DC 20201, 
                        *Phone:*
                         202 205-4321. *RIN:*
                         0991-AC08 93. Uniform Administrative Requirements, Costs Principles and Adult Requirements (45 CFR 75) (Rulemaking Resulting From a Section 610 Review) *Legal Authority:*5 U.S.C. 301 *Abstract:*
                         This will address the comments of the NPRM to 45 CFR 75 and to include additional provision that are not in conflict with OMB's language, and provide additional guidance regulated community. *Timetable:* Action
Date
FR CiteFinal Rule
12/12/16
81 FR 89393Final Rule Effective
01/17/17
 *Regulatory Flexibility Analysis Required:*
                         No. *Agency Contact:*
                         Quadira Dantro, Federal Assistance Policy Specialist, Department of Health and Human Services, Office of the Secretary, 200 Independence Avenue SW., Washington, DC 20201, 
                        *Phone:*
                         202 260-6825. *RIN:*
                         0991-AC09 DEPARTMENT OF HEALTH AND HUMAN SERVICES (HHS) Substance Abuse and Mental Health Services Administration (SAMHSA) Completed Actions 94. Requirements Governing the Use of Seclusion and Restraint in Certain Nonmedical Community-Based Facilities for Children and Youth *Legal Authority:*Pub. L. 106-310; 42 U.S.C. 290jj to 290jj-2 *Abstract:*
                         The Secretary is required by statute to publish regulations governing States that license nonmedical, community-based residential facilities for children and youth. The regulation would require States to develop licensing rules and monitoring requirements concerning behavior management practice that will ensure compliance; requires States to develop and implement such licensing rules and implementation requirements within one year; and ensures that States require such facilities to have adequate staff, and that the States provide training for professional staff. *Timetable:* Action
Date
FR CiteWithdrawn
06/08/17
 *Regulatory Flexibility Analysis Required:*
                         Yes. *Agency Contact:*
                         Paolo Del Vecchio, Associate Director for Consumer Affairs, Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Room 13-103, Parklawn Building, 5600 Fishers Lane, Rockville, MD 20857, 
                        *Phone:*
                         301 443-2619, 
                        *Email: paolo.delvecchio@samhsa.hhs.gov*. *RIN:*
                         0930-AA10 95. Medication Assisted Treatment for Opioid Use Disorders Reporting Requirements *Legal Authority:*21 U.S.C. 823(g)(2) *Abstract:*
                         On July 8, 2016, SAMHSA finalized a rule to increase access to buprenorphine and the combination buprenorphine/naloxone (Medication Assisted Treatment for Opioid Use Disorders). Concurrently with this final rule, SAMHSA issued a Supplemental Notice of Proposed Rulemaking seeking further comment on reporting provisions that would apply to physicians prescribing buprenorphine for up to 275 patients. *Timetable:* Action
Date
FR CiteNPRM
03/30/16
81 FR 17639NPRM Comment Period End
05/31/16Final Action
09/27/16
81 FR 66191Final Action Effective
10/27/16
 *Regulatory Flexibility Analysis Required:*
                         Yes. *Agency Contact:*
                         Brian Altman, Legislative Director, Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, 1 Choke Cherry Road, Rockville, MD 02857, 
                        *Phone:*
                         240 276-2009, 
                        *Email: brian.altman@samhsa.gov*. *RIN:*
                         0930-AA22 DEPARTMENT OF HEALTH AND HUMAN SERVICES (HHS) Centers for Disease Control and Prevention (CDC) Completed Actions 96. Establishment of Minimum Standards for Birth Certificates *Legal Authority:*42 U.S.C. 264 *Abstract:*
                         This proposed rule establishes minimum standards to improve security related to the use of birth certificates by Federal agencies for official purposes. *Timetable:* Action
Date
FR CiteWithdrawn
06/08/17
 
 
 *Regulatory Flexibility Analysis Required:*
                         Yes. *Agency Contact:*
                         Charles Rothwell, Director, Division of Vital Statistics, Department of Health and Human Services, Centers for Disease Control and Prevention, 3311 Toledo Road, Room 7311, M, Hyattsville, MD 20782, 
                        *Phone:*
                         301 458-4555. *RIN:*
                         0920-AA46 DEPARTMENT OF HEALTH AND HUMAN SERVICES (HHS) Food and Drug Administration (FDA) Final Rule Stage 97. Human Subject Protection; Acceptance of Data From Clinical Investigations for Medical Devices *Legal Authority:*21 U.S.C. 321; 21 U.S.C. 331; 21 U.S.C. 351; 21 U.S.C. 352; 21 U.S.C. 360; 21 U.S.C. 360c; 21 U.S.C. 360e; 21 U.S.C. 360i; 21 U.S.C. 360j; 21 U.S.C. 371; 21 U.S.C. 374; 21 U.S.C. 381; 21 U.S.C. 393; 42 U.S.C. 264; 42 U.S.C. 271; . . . *Abstract:*
                         This rule updates FDA's requirements for accepting clinical data used to bring new medical devices to market as part of fulfilling FDA's mission. While helping to ensure the quality and integrity of clinical trial data and the protection of study participants, this rule should reduce burden on industry by avoiding the need for on-site inspections. This rule parallels the drug regulation, which should further reduce burden by having a harmonized approach. Under this new rule, a device applicant would provide FDA with information about the conduct of their study such as, the research sites where the study was conducted, the investigators who conducted the study, a summary of the protocol, information about how informed consent from the study participants was obtained, and information about the ethics committee that reviewed the study. (If such information is not available, the sponsor may explain why and request a waiver.) *Timetable:* Action
Date
FR CiteNPRM
02/25/13
78 FR 12664NPRM Comment Period End
05/28/13Final Action
12/00/17
 *Regulatory Flexibility Analysis Required:*
                         Yes. *Agency Contact:*
                         Soma Kalb, Biomedical Engineer, Department of Health and Human Services, Food and Drug Administration, Center for Devices and Radiological Heath, Building 66, Room 1534, 10903 New Hampshire Avenue, Silver Spring, MD 20993, 
                        *Phone:*
                         301 796-6359, 
                        *Email: soma.kalb@fda.hhs.gov*. *RIN:*
                         0910-AG48 98. Food Labeling; Gluten-Free Labeling of Fermented, Hydrolyzed, or Distilled Foods *Legal Authority:*
                         Sec. 206 of the Food Allergen Labeling and Consumer Protection Act; 21 U.S.C. 343(a)(1); 21 U.S.C. 321(n); 21 U.S.C. 371(a) *Abstract:*
                         This proposed rule would establish requirements concerning compliance for using a “gluten-free” labeling claim for those foods for which there is no scientifically valid analytical method available that can reliably detect and accurately quantify the presence of 20 parts per million (ppm) gluten in the food. *Timetable:* Action
Date
FR CiteNPRM
11/18/15
80 FR 71990NPRM Comment Period Reopened
01/22/16
81 FR 3751NPRM Comment Period End
02/16/16NPRM Comment Period Reopened
02/22/16
81 FR 8869NPRM Comment Period Reopened End
04/25/16Final Rule
10/00/18
 *Regulatory Flexibility Analysis Required:*
                         Yes. *Agency Contact:*
                         Carol D'Lima, Staff Fellow, Department of Health and Human Services, Food and Drug Administration, Center for Food Safety and Applied Nutrition, Room 4D022, HFS 820, 5100 Paint Branch Parkway, College Park, MD 20740, 
                        *Phone:*
                         240 402-2371, 
                        *Fax:*
                         301 436-2636, 
                        *Email: carol.dlima@fda.hhs.gov*. *RIN:*
                         0910-AH00. 99. Safety and Effectiveness of Consumer Antiseptics; Topical Antimicrobial Drug Products for Over-the-Counter Human Use (Healthcare Antiseptic) *Legal Authority:*21 U.S.C. 321; 21 U.S.C. 331; 21 U.S.C. 351 to 353; 21 U.S.C. 355; 21 U.S.C. 360 to 361; 21 U.S.C. 371; 21 U.S.C. 374 to 375; 21 U.S.C. 379; 42 U.S.C. 216; 42 U.S.C. 241; 42 U.S.C. 262 *Abstract:*
                         This rulemaking addresses whether FDA considers certain active ingredients in over the counter (OTC) consumer antiseptic hand wash and health care antiseptic products to be generally recognized as safe and effective. If FDA determines that the ingredient is not generally recognized as safe and effective, a manufacturer will not be able to market the product unless it submits and receives approval of a new drug application. *Timetable:* Action
Date
FR CiteNPRM
12/17/13
78 FR 764444NPRM Comment Period End
06/16/14Final Action
01/00/18
 *Regulatory Flexibility Analysis Required:*
                         Yes. *Agency Contact:*
                         Pranvera Ikonomi, Biologist, Department of Health and Human Services, Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, MD 20993, 
                        *Phone:*
                         240 402-0272, 
                        *Email: pranvera.ikonomi@fda.hhs.gov*. *RIN:*
                         0910-AH40 DEPARTMENT OF HEALTH AND HUMAN SERVICES (HHS) Food and Drug Administration (FDA) Long-Term Actions 100. Postmarketing Safety Reporting Requirements for Human Drug and Biological Products *Legal Authority:*42 U.S.C. 216; 42 U.S.C. 241; 42 U.S.C. 242a; 42 U.S.C. 262 and 263; 42 U.S.C. 263a to 263n; 42 U.S.C. 264; 42 U.S.C. 300aa; 21 U.S.C. 321; 21 U.S.C. 331; 21 U.S.C. 351 to 353; 21 U.S.C. 355; 21 U.S.C. 360; 21 U.S.C. 360b to 360j; 21 U.S.C. 361a; 21 U.S.C. 371; 21 U.S.C. 374; 21 U.S.C. 375; 21 U.S.C. 379e; 21 U.S.C. 381 *Abstract:*
                         The final rule would amend the postmarketing expedited and periodic safety reporting regulations for human drugs and biological products to revise certain definitions and reporting formats as recommended by the International Council on Harmonisation and to define new terms; to add to or revise current reporting requirements; to revise certain reporting time frames; and to propose other revisions to these regulations to enhance the quality of safety reports received by FDA. These revisions were proposed as part of a single rulemaking (68 FR 12406) to clarify and revise both premarketing and postmarketing safety reporting requirements for human drug and biological products. Premarketing safety reporting requirements were finalized in a separate final rule published on September 29, 2010 (75 FR 59961). This 
                        ( print page 40282)
                        final rule applies to postmarketing safety reporting requirements. *Timetable:* Action
Date
FR CiteNPRM
03/14/03
68 FR 12406NPRM Comment Period Extended
06/18/03NPRM Comment Period End
07/14/03NPRM Comment Period Extension End
10/14/03Final Rule
10/00/18
 *Regulatory Flexibility Analysis Required:*
                         Yes. *Agency Contact:*
                         Jane E. Baluss, Regulatory Counsel, Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, WO 51, Room 6278, 10903 New Hampshire Avenue, Silver Spring, MD 20993-0002, 
                        *Phone:*
                         301 796-3469, 
                        *Fax:*
                         301 847-8440, 
                        *Email: jane.baluss@fda.hhs.gov*. *RIN:*
                         0910-AA97 101. Over-the-Counter (OTC) Drug Review—Cough/Cold (Antihistamine) Products *Legal Authority:*21 U.S.C. 321p; 21 U.S.C. 331; 21 U.S.C. 351 to 353; 21 U.S.C. 355; 21 U.S.C. 360; 21 U.S.C. 371 *Abstract:*
                         FDA will be proposing a rule to add the common cold indication to certain over-the-counter (OTC) antihistamine active ingredients. This proposed rule is the result of collaboration under the U.S.-Canada Regulatory Cooperation Council (RCC) as part of efforts to reduce unnecessary duplication and differences. This pilot exercise will help determine the feasibility of developing an ongoing mechanism for alignment in review and adoption of OTC drug monograph elements. *Timetable:* Action
Date
FR CiteReopening of Administrative Record
08/25/00
65 FR 51780Comment Period End
11/24/00NPRM (Amendment) (Common Cold)
10/00/18
 *Regulatory Flexibility Analysis Required:*
                         Yes. *Agency Contact:*
                         Janice Adams-King, Regulatory Health Project Manager, Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, WO 22, Room 5416, 10903 New Hampshire Avenue, Silver Spring, MD 20993, 
                        *Phone:*
                         301 796-3713, 
                        *Fax:*
                         301 796-9899, 
                        *Email: janice.adams-king@fda.hhs.gov*. *RIN:*
                         0910-AF31 102. Laser Products; Amendment to Performance Standard *Legal Authority:*21 U.S.C. 360hh to 360ss; 21 U.S.C. 371; 21 U.S.C. 393 *Abstract:*
                         FDA is proposing to amend the 2013 proposed rule for the performance standard for laser products, which will amend the performance standard for laser products to achieve closer harmonization between the current standard and the recently amended International Electrotechnical Commission (IEC) standard for laser products and medical laser products. The amendment is intended to update FDA's performance standard to reflect advancements in technology. *Timetable:* Action
Date
FR CiteNPRM
06/24/13
78 FR 37723NPRM Comment Period End
09/23/13NPRM (Reproposal)
10/00/18
 *Regulatory Flexibility Analysis Required:*
                         Yes. *Agency Contact:*
                         Erica Blake-Payne, Regulatory Counsel, Department of Health and Human Services, Food and Drug Administration, Center for Devices and Radiological Health, WO 66, Room 4426, 10903 New Hampshire Avenue, Silver Spring, MD 20993, 
                        *Phone:*
                         301 796-6248, 
                        *Fax:*
                         301 847-8145, 
                        *Email: erica.payne@fda.hhs.gov*. *RIN:*
                         0910-AF87 103. Updated Standards for Labeling of Pet Food *Legal Authority:*21 U.S.C. 343; 21 U.S.C. 371; Pub. L. 110-85, sec 1002(a)(3) *Abstract:*
                         FDA is proposing updated standards for the labeling of pet food that include nutritional and ingredient information, as well as style and formatting standards. FDA is taking this action to provide pet owners and animal health professionals more complete and consistent information about the nutrient content and ingredient composition of pet food products. *Timetable:*
                         Next Action Undetermined. *Regulatory Flexibility Analysis Required:*
                         Yes. *Agency Contact:*
                         William Burkholder, Veterinary Medical Officer, Department of Health and Human Services, Food and Drug Administration, Center for Veterinary Medicine, MPN-4, Room 2642, HFV-228, 7519 Standish Place, Rockville, MD 20855, 
                        *Phone:*
                         240 402-5900, 
                        *Email: william.burkholder@fda.hhs.gov*. *RIN:*
                         0910-AG09 104. Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products *Legal Authority:*21 U.S.C. 321; 21 U.S.C. 331; 21 U.S.C. 352; 21 U.S.C. 353; 21 U.S.C. 355; 21 U.S.C. 371; 42 U.S.C. 262; . . . *Abstract:*
                         This rule would amend the regulations regarding new drug applications (NDAs), abbreviated new drug applications (ANDAs), and biologics license application (BLAs) to revise and clarify procedures for changes to the labeling of an approved drug to reflect certain types of newly acquired information in advance of FDA's review of such change. *Timetable:* Action
Date
FR CiteNPRM
11/13/13
78 FR 67985NPRM Comment Period Extended
12/27/13
78 FR 78796NPRM Comment Period End
01/13/14NPRM Comment Period Extended End
03/13/14NPRM Comment Period Reopened
02/18/15
80 FR 8577NPRM Comment Period Reopened End
04/27/15Next Action Undetermined
 *Regulatory Flexibility Analysis Required:*
                         Yes. *Agency Contact:*
                         Janice L. Weiner, Senior Regulatory Counsel, Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Building 51, Room 6268, 10903 New Hampshire Avenue, Silver Spring, MD 20993-0002, 
                        *Phone:*
                         301 796-3601, 
                        *Fax:*
                         301 847-8440, 
                        *Email: janice.weiner@fda.hhs.gov*. *RIN:*
                         0910-AG94 105. Radiology Devices; Designation of Special Controls for the Computed Tomography X-Ray System *Legal Authority:*21 U.S.C. 360c *Abstract:*
                         The proposed rule would establish special controls for the computed tomography (CT) X-ray system. A CT X- ray system is a diagnostic X-ray imaging system intended to produce cross-sectional images of the body through use of a computer to reconstruct an image from 
                        ( print page 40283)
                        the same axial plane taken at different angles. High doses of ionizing radiation can cause acute (deterministic) effects such as burns, reddening of the skin, cataracts, hair loss, sterility, and, in extremely high doses, radiation poisoning. The design of a CT X-ray system should balance the benefits of the device (
                        *i.e.,*
                         the ability of the device to produce a diagnostic quality image) with the known risks (
                        *e.g.,*
                         exposure to ionizing radiation). FDA is establishing proposed special controls, which are necessary to provide reasonable assurance of the safety and effectiveness of a class II CT X-ray system. *Timetable:* Action
Date
FR CiteNPRM
10/00/18
 *Regulatory Flexibility Analysis Required:*
                         Yes. *Agency Contact:*
                         Erica Blake-Payne, Regulatory Counsel, Department of Health and Human Services, Food and Drug Administration, Center for Devices and Radiological Health, WO 66, Room 4426, 10903 New Hampshire Avenue, Silver Spring, MD 20993, 
                        *Phone:*
                         301 796-6248, 
                        *Fax:*
                         301 847-8145, 
                        *Email: erica.payne@fda.hhs.gov*. *RIN:*
                         0910-AH03 106. General and Plastic Surgery Devices: Sunlamp Products *Legal Authority:*21 U.S.C. 360j(e) *Abstract:*
                         This rule would apply device restrictions to sunlamp products. The incidence of skin cancer, including melanoma, has been increasing, and a large number of skin cancer cases are attributable to the use of sunlamp products. The devices may cause about 400,000 cases of skin cancer per year, and 6,000 of which are melanoma. Beginning sunlamp product use at young ages, as well as frequently using sunlamp products, both increase the risk of developing skin cancers and other illnesses, and sustaining other injuries. Even infrequent use, particularly at younger ages, can significantly increase these risks. Sunlamp products incorporate ultraviolet (UV) lamps and include devices such as UV tanning beds and booths. People who use sunlamp products are at increased risk of developing skin cancer and other illnesses, and sustaining injuries. *Timetable:* Action
Date
FR CiteNPRM
12/22/15
80 FR 79493NPRM Comment Period End
03/21/16Final Rule
10/00/18
 *Regulatory Flexibility Analysis Required:*
                         Yes. *Agency Contact:*
                         Ian Ostermiller, Regulatory Counsel, Department of Health and Human Services, Food and Drug Administration, Building 66, Room 5515, 10903 New Hampshire Avenue, Silver Spring, MD 20993, 
                        *Phone:*
                         301 796-5678, 
                        *Email: ian.ostermiller@fda.hhs.gov*. *RIN:*
                         0910-AH14 DEPARTMENT OF HEALTH AND HUMAN SERVICES (HHS) Food and Drug Administration (FDA) Completed Actions 107. Medical Gas Containers and Closures; Current Good Manufacturing Practice Requirements *Legal Authority:*21 U.S.C. 321; 21 U.S.C. 351 to 21 U.S.C. 353 *Abstract:*
                         The Food and Drug Administration is amending its current good manufacturing practice regulations and other regulations to clarify and strengthen requirements for the label, color, dedication, and design of medical gas containers and closures. Despite existing regulatory requirements and industry standards for medical gases, there have been repeated incidents in which cryogenic containers of harmful industrial gases have been connected to medical oxygen supply systems in hospitals and nursing homes and subsequently administered to patients. These incidents have resulted in death and serious injury. There have also been several incidents involving high-pressure medical gas cylinders that have resulted in death and injuries to patients. These amendments, together with existing regulations, are intended to ensure that the types of incidents that have occurred in the past, as well as other types of foreseeable and potentially deadly medical gas accidents, do not occur in the future. FDA has described a number of proposals in the proposed rule including requiring that gas use outlet connections on portable cryogenic medical gas containers be securely attached to the valve body. *Timetable:* Action
Date
FR CiteNPRM
04/10/06
71 FR 18039NPRM Comment Period End
07/10/06Final Action
11/18/16
81 FR 81685Final Action Effective
01/17/17
 *Regulatory Flexibility Analysis Required:*
                         Yes. *Agency Contact:*
                         Patrick Raulerson, Regulatory Counsel, Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, WO 51, Room 6368, 10903 New Hampshire Avenue, Silver Spring, MD 20993-0002, 
                        *Phone:*
                         301 796-3522, 
                        *Fax:*
                         301 847-8440, 
                        *Email: patrick.raulerson@fda.hhs.gov*. *RIN:*
                         0910-AC53 108. Amendment to the Current Good Manufacturing Practice Regulations for Finished Pharmaceuticals—Second Phase *Legal Authority:*21 U.S.C. 321; 21 U.S.C. 351; 21 U.S.C. 352; 21 U.S.C. 355; 21 U.S.C. 360b; 21 U.S.C. 371; 21 U.S.C. 374; 42 U.S.C. 262; 42 U.S.C. 264 *Abstract:*
                         FDA will revise regulations for “current good manufacturing practice” for oversight and controls over the manufacture of drugs to ensure quality, including managing the risk of and establishing the safety of raw materials, materials used in the manufacturing of drugs, and finished drug products. This revision will update and harmonize requirements and improve detection and response to emerging product safety and quality signals. *Timetable:* Action
Date
FR CiteWithdrawn
06/08/17
 *Regulatory Flexibility Analysis Required:*
                         Yes. *Agency Contact:*
                         Paula Katz, Regulatory Counsel, Office of Compliance, Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, WO 51, Room 4314, 10903 New Hampshire Avenue, Silver Spring, MD 20993, 
                        *Phone:*
                         301 796-6972, 
                        *Fax:*
                         301 847-8742, 
                        *Email: paula.katz@fda.hhs.gov*. *RIN:*
                         0910-AG20 109. Requirements for the Testing and Reporting of Tobacco Product Constituents, Ingredients, and Additives *Legal Authority:*21 U.S.C. 301 
                        *et seq.;*21 U.S.C. 387; The Family Smoking Prevention and Tobacco Control Act *Abstract:*
                         The Federal Food, Drug, and Cosmetic Act, as amended by the Family Smoking Prevention and Tobacco Control Act, requires the Food and Drug Administration to promulgate regulations that require the testing and reporting of tobacco product constituents, ingredients, and additives, 
                        ( print page 40284)
                        including smoke constituents, that the Agency determines should be tested to protect the public health. *Timetable:* Action
Date
FR CiteWithdrawn
04/05/17
 *Regulatory Flexibility Analysis Required:*
                         Yes. *Agency Contact:*
                         Laura Rich, Senior Regulatory Counsel, Department of Health and Human Services, Food and Drug Administration, Center for Tobacco Products, Building 71, G335, 10903 New Hampshire Avenue, Silver Spring, MD 20993, 
                        *Phone:*
                         877 287-1373, 
                        *Email: ctpregulations@fda.hhs.gov*. *RIN:*
                         0910-AG59 110. Amendments to the Current Good Manufacturing Practice Regulations for Finished Pharmaceuticals—Components *Legal Authority:*21 U.S.C. 321; 21 U.S.C. 351; 21 U.S.C. 352; 21 U.S.C. 355; 21 U.S.C. 360b; 21 U.S.C. 360bbb-7; 21 U.S.C. 371; 21 U.S.C. 374; 42 U.S.C. 262; 42 U.S.C. 264 *Abstract:*
                         FDA will revise regulations for “current good manufacturing practice” with regard to control over components used in manufacturing finished pharmaceuticals. *Timetable:* Action
Date
FR CiteWithdrawn
06/08/17
 *Regulatory Flexibility Analysis Required:*
                         Yes. *Agency Contact:*
                         Brian Hasselbalch, Consumer Safety Officer, Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, WO 51, Room 4364, 10903 New Hampshire Avenue, Silver Spring, MD 20993, 
                        *Phone:*
                         301 796-3279, 
                        *Email: brian.hasselbalch@fda.hhs.gov*. Paula Katz, Consumer Safety Officer, Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, WO 51, Room 1320, 10903 New Hampshire Avenue, Silver Spring, MD 20993, 
                        *Phone:*
                         301 796-6972, 
                        *Email: paula.katz@fda.hhs.gov*. *RIN:*
                         0910-AG70 111. Format and Content of Reports Intended To Demonstrate Substantial Equivalence *Legal Authority:*21 U.S.C. 387e(j); 21 U.S.C. 387j(a); 21 U.S.C. 371; 21 U.S.C. 374; 21 U.S.C. 387b; 21 U.S.C 387c; 21 U.S.C. 387i *Abstract:*
                         This regulation would establish the format and content of reports intended to demonstrate substantial equivalence. This regulation also would provide information as to how the Agency will review and act on these submissions. *Timetable:* Action
Date
FR CiteWithdrawn
04/05/17
 *Regulatory Flexibility Analysis Required:*
                         Yes. *Agency Contact:*
                         Annette L. Marthaler, Regulatory Counsel, Department of Health and Human Services, Food and Drug Administration, Center for Tobacco Products, Document Control Center, Building 71, Room G335, 10903 New Hampshire Avenue, Silver Spring, MD 20993, 
                        *Phone:*
                         877 287-1373, 
                        *Fax:*
                         877 287-1426, 
                        *Email: ctpregulations@fda.hhs.gov*. *RIN:*
                         0910-AG96 112. Investigational New Drug Application Annual Reporting *Legal Authority:*21 U.S.C. 321; 21 U.S.C. 331; 21 U.S.C. 351; 21 U.S.C. 352; 21 U.S.C. 353; 21 U.S.C. 355(i); 21 U.S.C. 371(a); 42 U.S.C. 262(a) *Abstract:*
                         This proposed rule would revise the requirements concerning annual reports submitted to investigational new drug applications (INDs) by replacing the current annual reporting requirement with a requirement that is generally consistent with the format, content, and timing of submission of the development safety update report devised by the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). *Timetable:* Action
Date
FR CiteWithdrawn
04/05/17
 *Regulatory Flexibility Analysis Required:*
                         Yes. *Agency Contact:*
                         Ebla Ali Ibrahim, Project Manager, Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Building 51, Room 6302, 10903 New Hampshire Avenue, Silver Spring, MD 20993, 
                        *Phone:*
                         301 796-3691, 
                        *Email: ebla.ali-ibrahim@fda.hhs.gov.* *RIN:*
                         0910-AH07 113. Requirements for Tobacco Product Manufacturing Practice *Legal Authority:*21 U.S.C. 371; 21 U.S.C. 387b; 21 U.S.C. 387f *Abstract:*
                         FDA is proposing requirements that govern the methods used in, and the facilities and controls used for, the pre-production design validation, manufacture, packing, and storage of tobacco products. *Timetable:* Action
Date
FR CiteANPRM
03/19/13
78 FR 16824ANPRM Comment Period End
05/20/13ANPRM Withdrawn
08/01/17
 *Regulatory Flexibility Analysis Required:*
                         Yes. *Agency Contact:*
                         Darin Achilles, Regulatory Counsel, Department of Health and Human Services, Food and Drug Administration, 10903 New Hampshire Avenue, Document Control Center, Building 71, Room G335, Silver Spring, MD 20993, 
                        *Phone:*
                         877 287-1373, 
                        *Fax:*
                         301 595-1426, 
                        *Email: ctpregulations@fda.hhs.gov.* *RIN:*
                         0910-AH22 114. Use of Ozone Depleting Substances (Section 610 Review) *Legal Authority:*21 U.S.C. 321; 21 U.S.C. 331; 21 U.S.C. 335; 21 U.S.C. 342; 21 U.S.C. 346a; 21 U.S.C. 348; 21 U.S.C. 351; 21 U.S.C. 352; 21 U.S.C. 355; 21 U.S.C. 360b; 21 U.S.C. 361; 21 U.S.C. 371; 21 U.S.C. 372; 21 U.S.C. 374; 15 U.S.C. 402; 15 U.S.C. 409 *Abstract:*
                         The Food and Drug Administration (FDA or the Agency) is proposing to amend its regulation (21 CFR 2.125) on uses of ozone-depleting substances (ODSs), including chlorofluorocarbons (CFCs), to remove designations for certain products as essential uses under the Clean Air Act. Essential-use products are exempt from FDA's ban on the use of CFC propellants in FDA-regulated products and the Environmental Protection Agency's (EPA's) ban on the use of CFCs and other ODSs in pressurized dispensers. This action, if finalized, will remove essential use exemptions for sterile aerosol talc administered intrapleurally by thoracoscopy for human use, metered-dose atropine sulfate aerosol human drugs administered by oral inhalation, and anesthetic drugs for topical use on accessible mucous membranes of humans where a cannula is used for application. FDA is proposing this action because alternative products that do not use ODSs are now available and because 
                        ( print page 40285)
                        these products are no longer being marketed in approved versions that contain ODSs. On June 29, 2015, FDA published a notice and request for comment concerning its tentative conclusion that these products are no longer an essential use under the Clean Air Act (80 FR 36937). The Agency received no comments concerning removal of essential use designations for sterile aerosol talc and metered-dose atropine sulfate, and is proposing to remove these designations by direct final rule and a companion proposed rule in the event adverse comments are received. FDA received one comment concerning removal of anesthetic drugs for topical use in response to its 2015 notice and request for comment, and is proposing to remove this exemption through a separate notice. Because these products are not currently sold in the approved form, no significant economic impact is anticipated. *Timetable:* Action
Date
FR CiteWithdrawn
06/30/17
 *Regulatory Flexibility Analysis Required:*
                         No. *Agency Contact:*
                         Daniel Orr, Regulatory Counsel, Department of Health and Human Services, Food and Drug Administration, Building 51, Room 5199, 10993 New Hampshire Avenue, Silver Spring, MD 20993, 
                        *Phone:*
                         240 402-0979, 
                        *Email: daniel.orr@fda.hhs.gov.* *RIN:*
                         0910-AH36 DEPARTMENT OF HEALTH AND HUMAN SERVICES (HHS) Centers for Medicare & Medicaid Services (CMS) Proposed Rule Stage 115. CY 2018 Revisions to Payment Policies Under the Physician Fee Schedule and Other Revisions to Medicare Part B (CMS-1676-P) (Section 610 Review) *Legal Authority:*42 U.S.C. 1302; 42 U.S.C. 1395hh *Abstract:*
                         This annual proposed rule would revise payment policies under the Medicare physician fee schedule, and make other policy changes to payment under Medicare Part B. These changes would apply to services furnished beginning January 1, 2018. *Timetable:* Action
Date
FR CiteNPRM
06/00/17
 *Regulatory Flexibility Analysis Required:*
                         Yes. *Agency Contact:*
                         Ryan Howe, Director, Division of Practitioner Services, Department of Health and Human Services, Centers for Medicare & Medicaid Services, Center for Medicare, MS: C4-01-15, 7500 Security Boulevard, Baltimore, MD 21244, 
                        *Phone:*
                         410 786-3355, 
                        *Email: ryan.howe@cms.hhs.gov.* *RIN:*
                         0938-AT02 116. CY 2018 Hospital Outpatient PPS Policy Changes and Payment Rates and Ambulatory Surgical Center Payment System Policy Changes and Payment Rates (CMS-1678-P) (Section 610 Review) *Legal Authority:*42 U.S.C. 1302; 42 U.S.C. 1395hh *Abstract:*
                         This annual proposed rule would revise the Medicare hospital outpatient prospective payment system to implement statutory requirements and changes arising from our continuing experience with this system. The proposed rule describes changes to the amounts and factors used to determine payment rates for services. In addition, the rule proposes changes to the ambulatory surgical center payment system list of services and rates. *Timetable:* Action
Date
FR CiteNPRM
06/00/17
 *Regulatory Flexibility Analysis Required:*
                         Yes. *Agency Contact:*
                         Lela Strong, Health Insurance Specialist, Department of Health and Human Services, Centers for Medicare & Medicaid Services, Center for Medicare, MS: C4-05-13, 7500 Security Boulevard, Baltimore, MD 21244, 
                        *Phone:*
                         410 786-3213, 
                        *Email: lela.strong@cms.hhs.gov.* *RIN:*
                         0938-AT03 117. • CY 2019 Notice of Benefit and Payment Parameters (CMS-9930-P) (Section 610 Review) *Legal Authority:*Pub. L. 111-148. *Abstract:*
                         This proposed rule would set forth payment parameters and provisions related to the risk adjustment programs; cost sharing parameters and cost-sharing reductions; and user fees for Federally-Facilitated Exchanges. It would also provide additional standards for several other Affordable Care Act programs. *Timetable:* Action
Date
FR CiteNPRM
09/00/17
 *Regulatory Flexibility Analysis Required:*
                         Yes. *Agency Contact:*
                         Lindsey Murtagh, Health Insurance Specialist, Department of Health and Human Services, Centers for Medicare & Medicaid Services, Center for Consumer Information and Insurance Oversight, 7500 Security Boulevard, Baltimore, MD 21244, 
                        *Phone:*
                         301 492-4106, 
                        *Email: lindsey.murtagh@cms.hhs.gov.* *RIN:*
                         0938-AT12 DEPARTMENT OF HEALTH AND HUMAN SERVICES (HHS) Centers for Medicare & Medicaid Services (CMS) Final Rule Stage 118. Hospital Inpatient Prospective Payment System for Acute Care Hospitals and the Long-Term Care Hospital Prospective Payment System and FY 2018 Rates (CMS-1677-P) (Section 610 Review) *Legal Authority:*42 U.S.C. 1302; 42 U.S.C. 1395hh; Pub. L. 114-255 *Abstract:*
                         This annual final rule would revise the Medicare hospital inpatient and long-term care hospital prospective payment systems for operating and capital-related costs. This rule implements changes arising from our continuing experience with these systems. *Timetable:* Action
Date
FR CiteNPRM
04/28/17
82 FR 19796NPRM Comment Period End
06/13/17Final Action
08/00/17
 *Regulatory Flexibility Analysis Required:*
                         Yes. *Agency Contact:*
                         Donald Thompson, Deputy Director, Division of Acute Care, Department of Health and Human Services, Centers for Medicare & Medicaid Services, Center for Medicare, MS: C4-08-06, 7500 Security Boulevard, Baltimore, MD 21244, 
                        *Phone:*
                         410 786-6504, 
                        *Email: donald.thompson@cms.hhs.gov.* *RIN:*
                         0938-AS98 
 
 DEPARTMENT OF HEALTH AND HUMAN SERVICES (HHS) Centers for Medicare & Medicaid Services (CMS) Long-Term Actions 119. Hospital and Critical Access Hospital (CAH) Changes To Promote Innovation, Flexibility, and Improvement in Patient Care (CMS-3295-F) (Rulemaking Resulting from a Section 610 Review) *Legal Authority:*42 U.S.C. 1302; 42 U.S.C. 1395hh and 1395rr *Abstract:*
                         This final rule updates the requirements that hospitals and critical access hospitals (CAHs) must meet to participate in the Medicare and Medicaid programs. These final requirements are intended to conform the requirements to current standards of practice and support improvements in quality of care, reduce barriers to care, and reduce some issues that may exacerbate workforce shortage concerns. *Timetable:* Action
Date
FR CiteNPRM
06/16/16
81 FR 39447NPRM Comment Period End
08/15/16Final Action
06/00/19
 *Regulatory Flexibility Analysis Required:*
                         No. *Agency Contact:*
                         CDR Scott Cooper, Senior Technical Advisor, Department of Health and Human Services, Centers for Medicare & Medicaid Services, Center for Clinical Standards and Quality, Mail Stop S3-01-02, 7500 Security Boulevard, Baltimore, MD 21244, 
                        *Phone:*
                         410 786-9465, 
                        *Email: scott.cooper@cms.hhs.gov.* *RIN:*
                         0938-AS21 DEPARTMENT OF HEALTH AND HUMAN SERVICES (HHS) Centers for Medicare & Medicaid Services (CMS) Completed Actions 120. Imaging Accreditation (CMS-3309-P) *Legal Authority:*42 U.S.C. 1395hh; 42 U.S.C. 1102 *Abstract:*
                         This proposed rule would establish standards for imaging accreditation for advanced diagnostic imaging services. These proposed standards would address qualifications for clinical personnel, standards to ensure that suppliers have established policies and procedures governing the use of equipment in furnishing the technical component of advanced diagnostic imaging, and the establishment and maintenance of a quality assurance and quality control program to ensure reliability, clarity and accuracy of the diagnostic images. This proposed rule would also address oversight of CMS approved accrediting organizations with imaging accreditation programs. *Timetable:* Action
Date
FR CiteWithdrawn
03/23/17
 *Regulatory Flexibility Analysis Required:*
                         Yes. *Agency Contact:*
                         Sonia Swancy, Health Insurance Specialist, Department of Health and Human Services, Centers for Medicare & Medicaid Services, Center for Clinical Standards and Quality, MS: S3-02-01, 7500 Security Boulevard, Baltimore, MD 21244, 
                        *Phone:*
                         410 786-8445, 
                        *Email: sonia.swancy@cms.hhs.gov.* *RIN:*
                         0938-AS62 121. Merit-Based Incentive Payment System (MIPS) and Alternative Payment Models (APMS) in Medicare Fee-For-Service (CMS-5517-FC) (Completion of a Section 610 Review) *Legal Authority:*Pub. L. 114-10, sec. 101 *Abstract:*
                         This rule implements provisions of the Medicare Access and CHIP Reauthorization Act (MACRA) related to MIPS and APMs. Section 101 of MACRA authorizes a new MIPS, which repeals the Medicare sustainable growth rate and improves Medicare payments for physician services. MACRA consolidates the current programs of the Physician Quality Reporting System, the Value-Based Modifier, and the Electronic Health Records Incentive Program into one program, MIPS, that streamlines and improves on the three distinct incentive programs. Additionally, MACRA authorizes incentive payments for providers who participate in eligible APMs. *Timetable:* Action
Date
FR CiteNPRM
05/09/16
81 FR 28161NPRM Comment Period End
06/27/16Final Action
11/04/16
81 FR 77088Final Action Effective
01/01/17
 *Regulatory Flexibility Analysis Required:*
                         Yes. *Agency Contact:*
                         Molly MacHarris, Health Insurance Specialist, Department of Health and Human Services, Centers for Medicare & Medicaid Services, Center for Clinical Standards & Quality, MS: S3-02-01, 7500 Security Boulevard, Baltimore, MD 21244, 
                        *Phone:*
                         410 786-4461, 
                        *Email: molly.macharris@cms.hhs.gov.* James Sharp, Health Insurance Specialist, Department of Health and Human Services, Centers for Medicare & Medicaid Services, Center for Medicare & Medicaid Innovation Center, MS: WB-06-05, 7500 Security Boulevard, Baltimore, MD 21244, 
                        *Phone:*
                         410 786-7388, 
                        *Email: james.sharp@cms.hhs.gov.* *RIN:*
                         0938-AS69 122. CY 2017 Home Health Prospective Payment System Rate Update; Home Health Value-Based Purchasing Model; and Home Health Quality Reporting Requirements (CMS-1648-F) (Completion of a Section 610 Review) *Legal Authority:*42 U.S.C. 1302; 42 U.S.C. 1395hh *Abstract:*
                         This annual rule updates the 60-day national episode rate, the national per-visit rates used to calculate low utilization payment adjustments (LUPAs), and outlier payments under the Medicare prospective payment system for home health agencies. The rule also updates the provisions of the Home Health Value-Based Purchasing (HHVBP) program. *Timetable:* Action
Date
FR CiteNPRM
07/05/16
81 FR 43714NPRM Comment Period End
08/26/16Final Action
11/03/16
81 FR 76702Final Action Effective
01/01/17
 *Regulatory Flexibility Analysis Required:*
                         Yes. *Agency Contact:*
                         Hillary Loeffler, Director, Division of Home Health and Hospice, Department of Health and Human Services, Centers for Medicare & Medicaid Services, Center for Medicare, MS: C5-07-22, 7500 Security Boulevard, Baltimore, MD 21244, 
                        *Phone:*
                         410 786-0456, 
                        *Email: hillary.loeffler@cms.hhs.gov.* *RIN:*
                         0938-AS80 123. CY 2017 Revisions to Payment Policies Under the Physician Fee Schedule and Other Revisions to Medicare Part B (CMS-1654-F) (Completion of a Section 610 Review) *Legal Authority:*42 U.S.C. 1302; 42 U.S.C. 1395hh; Pub. L. 114-10 *Abstract:*
                         This annual rule revises payment policies under the Medicare physician fee schedule, and make other policy changes to payment under 
                        ( print page 40287)
                        Medicare Part B. These changes apply to services furnished beginning January 1, 2017. *Timetable:* Action
Date
FR CiteNPRM
07/15/16
81 FR 46162NPRM Comment Period End
09/06/16Final Action
11/15/16
81 FR 80170Final Action Effective
01/01/17
 *Regulatory Flexibility Analysis Required:*
                         Yes. *Agency Contact:*
                         Ryan Howe, Director, Division of Practitioner Services, Department of Health and Human Services, Centers for Medicare & Medicaid Services, Center for Medicare, MS: C4-01-15, 7500 Security Boulevard, Baltimore, MD 21244, 
                        *Phone:*
                         410 786-3355, 
                        *Email: ryan.howe@cms.hhs.gov.* *RIN:*
                         0938-AS81 124. CY 2017 Hospital Outpatient PPS Policy Changes and Payment Rates and Ambulatory Surgical Center Payment System Policy Changes and Payment Rates (CMS-1656-FC) (Completion of a Section 610 Review) *Legal Authority:*42 U.S.C. 1302; 42 U.S.C. 1395hh *Abstract:*
                         This annual rule revises the Medicare hospital outpatient prospective payment system to implement statutory requirements and changes arising from our continuing experience with this system. The rule describes changes to the amounts and factors used to determine payment rates for services. In addition, the rule changes the ambulatory surgical center payment system list of services and rates. *Timetable:* Action
Date
FR CiteNPRM
07/14/16
81 FR 45604NPRM Comment Period End
09/06/16Final Action
11/14/16
81 FR 79562Final Action Effective
01/01/17
 *Regulatory Flexibility Analysis Required:*
                         Yes. *Agency Contact:*
                         Lela Strong, Health Insurance Specialist, Department of Health and Human Services, Centers for Medicare & Medicaid Services, Center for Medicare, MS: C4-05-13, 7500 Security Boulevard, Baltimore, MD 21244, 
                        *Phone:*
                         410 786-3213, 
                        *Email: lela.strong@cms.hhs.gov.* *RIN:*
                         0938-AS82


[FR Doc. 2017-16920 Filed 8-23-17; 8:45 am] BILLING CODE 4150-03-P